MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is a publicly traded Healthcare sector company. As of July 6, 2026, MIRA trades at $0.92 with a market cap of $39.70M and a P/E ratio of -0.70. MIRA moved +0.00% today. Year to date, MIRA is -36.59%; over the trailing twelve months it is -23.81%. Its 52-week range spans $0.73 to $2.45. Rallies surfaces MIRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MIRA Advances SKNY-1 Oral Candidate with 6-12h Peak Plasma, Brain and Liver Exposure: Preclinical studies of MIRA’s SKNY-1 oral formulation showed favorable bioavailability, robust brain penetration and substantial liver exposure, with peak plasma concentrations at six to twelve hours post-dose. These pharmacokinetic results support potential once-daily dosing and strengthen SKNY-1’s development profile for obesity and addiction therapy.
| Metric | Value |
|---|---|
| Price | $0.92 |
| Market Cap | $39.70M |
| P/E Ratio | -0.70 |
| EPS | $-1.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.45 |
| 52-Week Low | $0.73 |
| Volume | 41.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-10.44M |
| Gross Margin | 0.00% |
MIRA analyst coverage data. Average price target: $0.00.